A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations

Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis

Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B. R., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,358 · see citing works

Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

Horton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., Brown, M. S., & Goldstein, J. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1534923100 · Cited by 1,427 · see citing works

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9

Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381 · see citing works

Universally Sloppy Parameter Sensitivities in Systems Biology Models

Gutenkunst, R. N., Waterfall, J. J., Casey, F. P., Brown, K. S., Myers, C. R., & Sethna, J. P. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030189 · Cited by 1,261 · see citing works

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664 · see citing works

Molecular biology of PCSK9: its role in LDL metabolism

HORTON, J., COHEN, J., & HOBBS, H. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.12.008 · Cited by 621 · see citing works

Statins Upregulate PCSK9 , the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia

Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N. G., Bernier, L., & Prat, A. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000134621.14315.43 · Cited by 614 · see citing works

General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

Mager, D. E., & Jusko, W. J. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1014414520282 · Cited by 605 · see citing works

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 575 · see citing works

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

McKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 507 · see citing works

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

Raal, F. J., Scott, R. C., Somaratne, R. M., Bridges, I. M., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 502 · see citing works

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., & Stein, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201832 · Cited by 459 · see citing works

LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management

Cromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., SULLIVAN, L. M., Vasan, R. S., Wilson, P. W. F., & D’Agostino, R. B. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.10.001 · Cited by 428 · see citing works

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

Giugliano, R. P., Desai, N. R., Kohli, P., Rogers, W. J., Somaratne, R. M., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E. B., McDonald, S. T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61770-x · Cited by 425 · see citing works

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9

Careskey, H. E., Davis, R., Alborn, W. E., Troutt, J. S., Cao, G., & Konrad, R. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700437-jlr200 · Cited by 313 · see citing works

Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry

Bosner, M. S., Lange, L. G., Stenson, W. F., & Ostlund, R. E. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33370-8 · Cited by 310 · see citing works

Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development

van der Graaf, P. H., & Benson, N. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0467-9 · Cited by 248 · see citing works

Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal

Sacks, F. M., & Campos, H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030636 · Cited by 241 · see citing works

Update and Analysis of the University College London Low Density Lipoprotein Receptor Familial Hypercholesterolemia Database

Leigh, S. E. A., Foster, A. H., Whittall, R., Hubbart, C., & Humphries, S. E. (2008) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2008.00436.x · Cited by 236 · see citing works

Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels

Dias, C. S., Shaywitz, A. J., Wasserman, S. M., Smith, B. P., Gao, B., Stolman, D., Crispino, C., Smirnakis, K. V., Emery, M. G., Colbert, A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.986 · Cited by 230 · see citing works

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

Mayne, J., Dewpura, T., Raymond, A., Cousins, M., Chaplin, A., Lahey, K. A., LaHaye, S. A., Mbikay, M., Ooi, T. C., & Chrétien, M. (2008) · Lipids in Health and Disease · doi:10.1186/1476-511x-7-22 · Cited by 216 · see citing works

A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling

Peterson, M. C., & Riggs, M. M. (2010) · Bone · doi:10.1016/j.bone.2009.08.053 · Cited by 198 · see citing works

Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse.

Osono, Y., Woollett, L. A., Herz, J., & Dietschy, J. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117760 · Cited by 188 · see citing works

Statins as Potent Antiinflammatory Drugs

Lefer, D. J. (2002) · Circulation · doi:10.1161/01.cir.0000033635.42612.88 · Cited by 182 · see citing works

The formation of LDL: mechanisms and regulation

Havel, R. J. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34434-5 · Cited by 146 · see citing works

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy

Raal, F. J., Panz, V. R., Immelman, A., & Pilcher, G. J. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.000028 · Cited by 132 · see citing works

Computational Modeling of ERBB2 -Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors

Kirouac, D. C., Du, J. Y., Lahdenranta, J., Overland, R. P., Yarar, D., Paragas, V. B., Pace, E. A., McDonagh, C. F., Nielsen, U. B., & Onsum, M. D. (2013) · Science Signaling · doi:10.1126/scisignal.2004008 · Cited by 105 · see citing works

A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation

Auley, M. T. M., Wilkinson, D. J., Jones, J. J., & Kirkwood, T. B. L. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-130 · Cited by 102 · see citing works

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes

Zhang, L., McCabe, T. J. D., Condra, J. H., Ni, Y. G., Peterson, L. B., Wang, W., Strack, A. M., Wang, F., Pandit, S., Hammond, H. A., et al. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.3524 · Cited by 101 · see citing works

Pharmacodynamics and Pharmacokinetic-Pharmacodynamic Relationships of Atorvastatin, an HMG-CoA Reductase Inhibitor

Stern, R. H., Yang, B., Hounslow, N. J., MacMahon, M., Abel, R. B., & Olson, S. C. (2000) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2000.tb05987.x · Cited by 82 · see citing works

Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis

Schmidt, B. J., Casey, F., Paterson, T. S., & Chan, J. R. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-221 · Cited by 73 · see citing works

Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective

Mohammadpour, A. H., & Akhlaghi, F. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0071-8 · Cited by 69 · see citing works

Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men

Sudhop, T., Reber, M., Tribble, D. L., Sapre, A., Taggart, W. V., Gibbons, P. H., Musliner, T., von Bergmann, K., & Lütjohann, D. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p900004-jlr200 · Cited by 68 · see citing works

Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?

Chan, D. C., Lambert, G. C., Barrett, P. H. R., Rye, K., Ooi, E. M. M., & Watts, G. F. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.128645 · Cited by 62 · see citing works

The Type 1 Diabetes PhysioLab® Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse

Shoda, L. K. M., Kreuwel, H. T. C., Gadkar, K. G., Zheng, Y., Whiting, C. C., Atkinson, M. A., Bluestone, J. A., Mathis, D. J., Young, D. L., & Ramanujan, S. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04166.x · Cited by 56 · see citing works

Systems biology for battling rheumatoid arthritis: Application of the Entelos PhysioLab platform

Rullmann, J. A. C., Struemper, H., Defranoux, N. A., Ramanujan, S., Meeuwisse, C. M., & van Elsas, A. (2005) · Systems Biology · doi:10.1049/ip-syb:20050053 · Cited by 56 · see citing works

PCSK9: an emerging target for treatment of hypercholesterolemia

Duff, C. J., & Hooper, N. M. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.547480 · Cited by 50 · see citing works

Anti-PCSK9 therapies for the treatment of hypercholesterolemia

Hooper, A. J., & Burnett, J. R. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.748743 · Cited by 46 · see citing works

Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?

Barter, P. J., & Rye, K. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.004 · Cited by 27 · see citing works

Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study

Tingley, W. G., Luca, D., Leabman, M. K., Budha, N. R., Kahn, R., Baruch, A., Cowan, K. J., & Davis, J. C. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht309.p4183 · Cited by 8 · see citing works

Clinical pharmacology considerations for the development of immune checkpoint inhibitors

Sheng, J., Srivastava, S., Sanghavi, K., Lu, Z., Schmidt, B. J., Bello, A., & Gupta, M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.990 · Cited by 124 · see citing works

Improving the generation and selection of virtual populations in quantitative systems pharmacology models

Rieger, T. R., Allen, R. J., Bystricky, L., Chen, Y., Colopy, G. W., Cui, Y., Gonzalez, A., Liu, Y., White, R. D., Everett, R. A., et al. (2018) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2018.06.002 · Cited by 94 · see citing works

A Six‐Stage Workflow for Robust Application of Systems Pharmacology

Gadkar, K., Kirouac, D., Mager, D., van der Graaf, P., & Ramanujan, S. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12071 · Cited by 93 · see citing works

QSP toolbox: computational implementation of integrated workflow components for deploying multi-scale mechanistic models.

Cheng, Y., Thalhauser, C. J., Smithline, S., Pagidala, J., Miladinov, M., Vezina, H. E., Gupta, M., Leil, T. A., & Schmidt, B. J. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0100-x · Cited by 54 · see citing works

Reproducibility of Quantitative Systems Pharmacology Models: Current Challenges and Future Opportunities

Kirouac, D. C., Cicali, B., & Schmidt, S. (2019) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12390 · Cited by 46 · see citing works

Development and functional analysis of novel PCSK9/LDLR interaction inhibitors for hypercholesterolemia treatment

Yokoyama, T., Ando, T., Fuji, D., et al. (2021) · Proceedings for Annual Meeting of The Japanese Pharmacological Society · doi:10.1254/jpssuppl.94.0_1-p2-04

LDLR, PCSK9, and LDLRAP1 mutations in the same patient in a familial hypercholesterolemia (FH) family

Cocci, G., Cenci, A., Bordicchia, M., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.755

On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects

Tavori, H., Rashid, S., & Fazio, S. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.017 · Cited by 86 · see citing works

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis

Guo, Q., Feng, X., & Zhou, Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.01020 · Cited by 58 · see citing works

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

Canuel, M., Sun, X., Asselin, M.-C., Paramithiotis, E., Prat, A., & Seidah, N. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064145 · Cited by 227 · see citing works